MYC and diffuse large B-cell lymphoma: In summary we not only provide a model with high predictive efficacy for predicting the survival of patients with DLBCL but also demonstrated that drugs that compromising MYC target genes rather than ICIs may be beneficial to DLBCL patients with specific lipid metabolism status.